Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Thermo Fisher Scientific Inc. ofrece soluciones de ciencias biológicas, instrumentos analíticos, diagnósticos especializados y productos de laboratorio y servicios biofarmacéuticos a nivel internacional. Opera a través de cuatro segmentos: Soluciones de ciencias biológicas, instrumentos analíticos, diagnóstico especializado y productos de laboratorio y servicios biofarmacéuticos.
Traducido automáticamente
Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →
| Cuenta de resultados | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos totales | $46.3B | $44.6B | $42.9B | $42.9B | $44.9B | $39.2B | $32.2B | $25.5B | $24.4B | $20.9B | $18.3B | $17.0B | $16.9B | $13.1B | $12.5B | $11.7B | $10.8B | $10.1B | $10.5B | $9.7B | $3.8B |
| Beneficio bruto | $18.7B | $16.8B | $17.7B | $17.6B | $19.0B | $19.6B | $16.0B | $11.3B | $11.0B | $9.7B | $8.6B | $7.8B | $7.9B | $5.6B | $5.4B | $4.9B | $4.3B | $4.1B | $4.2B | $3.9B | $1.7B |
| % de margen bruto | 40.4% | 37.7% | 41.3% | 41.0% | 42.3% | 50.1% | 49.8% | 44.4% | 45.1% | 46.3% | 47.0% | 46.2% | 46.7% | 43.0% | 43.3% | 41.5% | 39.6% | 40.3% | 40.4% | 40.0% | 44.5% |
| Ingresos operativos (EBIT) | $8.2B | $8.1B | $7.7B | $6.9B | $8.5B | $10.3B | $7.9B | $4.3B | $3.9B | $3.3B | $2.9B | $2.5B | $2.3B | $1.8B | $1.6B | $1.5B | $1.3B | $1.1B | $1.3B | $1.1B | $365M |
| % de margen operativo | 17.7% | 18.2% | 17.9% | 16.0% | 19.0% | 26.3% | 24.5% | 16.7% | 15.9% | 15.6% | 15.6% | 14.7% | 13.9% | 13.7% | 13.0% | 12.6% | 11.7% | 11.1% | 12.1% | 10.9% | 9.6% |
| Ingresos netos | $7.0B | $6.7B | $6.3B | $6.0B | $7.0B | $7.7B | $6.4B | $3.7B | $2.9B | $2.2B | $2.0B | $2.0B | $1.9B | $1.3B | $1.2B | $1.3B | $1.0B | $850M | $994M | $761M | $169M |
| % de margen neto | 15.1% | 15.1% | 14.8% | 14.0% | 15.5% | 19.7% | 19.8% | 14.5% | 12.1% | 10.6% | 11.1% | 11.6% | 11.2% | 9.7% | 9.4% | 11.3% | 9.6% | 8.4% | 9.5% | 7.8% | 4.5% |
| EBITDA | $10.9B | $11.5B | $11.8B | $6.9B | $11.9B | $12.0B | $10.1B | $7.0B | $6.2B | $5.1B | $4.3B | $4.0B | $4.3B | $2.6B | $2.5B | $2.2B | $1.9B | $1.8B | $2.1B | $1.8B | $502M |
| Beneficio por acción (EPS) | $18.62 | $17.87 | $16.54 | $15.45 | $17.64 | $19.46 | $15.98 | $9.17 | $7.24 | $5.59 | $5.09 | $4.92 | $4.71 | $3.48 | $3.21 | $3.46 | $2.53 | $2.01 | $2.29 | $1.72 | $0.83 |
| Acciones en circulación (M) | 371M | 377M | 383M | 388M | 394M | 397M | 399M | 403M | 406M | 398M | 397M | 402M | 402M | 366M | 367M | 385M | 409M | 423M | 435M | 444M | 204M |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de TMO. /companies/us/TMO
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms